Radiopharm Theranostics L... (RADX)
Radiopharm Theranostics Statistics
Share Statistics
Radiopharm Theranostics has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is null and the forward PE ratio is null.
| PE Ratio | null |
| Forward PE | n/a |
| PS Ratio | null |
| Forward PS | null |
| PB Ratio | null |
| P/FCF Ratio | null |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics Limited.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of null, with a Debt / Equity ratio of null.
| Current Ratio | null |
| Quick Ratio | null |
| Debt / Equity | null |
| Total Debt / Capitalization | - |
| Cash Flow / Debt | null |
| Interest Coverage | null |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is null%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | null% |
| Revenue Per Employee | $undefined |
| Profits Per Employee | $undefined |
| Employee Count | undefined |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | - |
| Effective Tax Rate | null |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.89, so Radiopharm Theranostics's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 5.24 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 50.77 |
| Average Volume (20 Days) | 224.48K |
Income Statement
| Revenue | n/a |
| Gross Profit | - |
| Operating Income | - |
| Net Income | - |
| EBITDA | - |
| EBIT | n/a |
| Earnings Per Share (EPS) | null |
Balance Sheet
The company has - in cash and - in debt, giving a net cash position of 0.
| Cash & Cash Equivalents | - |
| Total Debt | - |
| Net Cash | 0 |
| Retained Earnings | - |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was - and capital expenditures -, giving a free cash flow of -.
| Operating Cash Flow | - |
| Capital Expenditures | - |
| Free Cash Flow | - |
| FCF Per Share | null |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RADX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RADX is $15, which is 170.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 170.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |